Aura Biosciences, Inc. (AURA): Price and Financial Metrics


Aura Biosciences, Inc. (AURA): $17.01

0.53 (+3.22%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add AURA to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

AURA Stock Price Chart Interactive Chart >

Price chart for AURA

AURA Price/Volume Stats

Current price $17.01 52-week high $26.16
Prev. close $16.48 52-week low $13.50
Day low $16.26 Volume 57,000
Day high $17.27 Avg. volume 36,492
50-day MA $18.48 Dividend yield N/A
200-day MA $0.00 Market Cap 497.71M

Aura Biosciences, Inc. (AURA) Company Bio


Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform to treat tumors of high unmet need in ocular and urologic oncology. Its AU-011, a VDC candidate, is being developed for the first line treatment of primary choroidal melanoma, a rare disease with no drugs approved. The company also develops AU-011 in additional ocular oncology indications, including choroidal metastases. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.


AURA Latest News Stream


Event/Time News Detail
Loading, please wait...

AURA Latest Social Stream


Loading social stream, please wait...

View Full AURA Social Stream

Latest AURA News From Around the Web

Below are the latest news stories about Aura Biosciences Inc that investors may wish to consider to help them evaluate AURA as an investment opportunity.

Aura Biosciences to Present Preclinical Data Demonstrating Applicability of AU-011 in Bladder Cancer at the 2022 ASCO Genitourinary Cancer Symposium

CAMBRIDGE, Mass., February 14, 2022--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the presentation of preclinical data for its first VDC product candidate, AU-011, which is being developed for the treatment of Non-Muscle Invasive Bladder Cancer (NMIBC). The results will be presented as part of the 2022 American Society of Clinical Oncology (ASCO

Yahoo | February 14, 2022

Aura Biosciences to Participate at the 11th Annual SVB Leerink Global Healthcare Conference

CAMBRIDGE, Mass., February 09, 2022--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer of Aura, will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare conference taking place on Wednesday, February 16, 2022, at 8:40 a.m. Eastern Time.

Yahoo | February 9, 2022

Medicxi Ventures Management (Jersey) Ltd Buys Aura Biosciences Inc

Investment company Medicxi Ventures Management (Jersey) Ltd (Current Portfolio) buys Aura Biosciences Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Medicxi Ventures Management (Jersey) Ltd.

Yahoo | February 3, 2022

What Percentage Of Aura Biosciences, Inc. (NASDAQ:AURA) Shares Do Insiders Own?

The big shareholder groups in Aura Biosciences, Inc. ( NASDAQ:AURA ) have power over the company. Institutions often...

Yahoo | January 29, 2022

Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and Aura Biosciences Inc (AURA)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Merck & Company (MRK – Research Report) and Aura Biosciences Inc (AURA – Research Report) with bullish sentiments. Merck & Company (MRK) Leerink Partners analyst Daina Graybosch maintained a Buy rating on Merck & Company yesterday and set a price target of $102.00. The company's shares closed last Monday at $74.89. According to TipRanks.

Ryan Adist on TipRanks | November 30, 2021

Read More 'AURA' Stories Here

AURA Price Returns

1-mo 0.29%
3-mo -4.97%
6-mo -2.47%
1-year N/A
3-year N/A
5-year N/A
YTD 0.18%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5219 seconds.